Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact email@example.com.
Oct 11, 2018
Cardiff University and Cytox to present research showing polygenic risk score approach predicts Alzheimer’s Disease and mild cognitive impairment better than APOE in ADNI dataset
Research results to be presented at ASHG Oct. 16-20
Professor Valentina Escott-Price is speaking at 11:00 am at Session 17 – Clinical Spotlight: Realizing the Promise of Common Genomic Variation in Rare and Common Disease: Clinical Implementation of Polygenic Risk Scores, 10:30 am –12:30 pm, in the Ballroom 20BC, Upper Level, San Diego Convention Center on Wednesday, October 17. The presentation is titled ‘Polygenic risk score analysis in the pre-symptomatic prediction and diagnosis of Alzheimer’s disease.’
The poster, 3385T, ‘Polygenic risk score predicts mild cognitive impairment and Alzheimer’s disease significantly better than APOE in ADNI dataset’ is being displayed as part of the Statistical Genetics and Genetic Epidemiology session in the Exhibit Hall – Ground Level at the San Diego Convention Center, 2:00 – 4:00 pm. It presents the results from a collaborative study carried out by the MRC-Centre for Neuropsychiatric Genetics and Genomics, Cardiff, UK, the Institute of Neurology, University College London, UK, Cytox Ltd, Oxford, UK, Edith Cowan University and Cooperative research Centre for Mental Health, Perth, Australia and the Dementia Research Institute at Cardiff, UK.